Ticker
ABBV

Price
146.38
Stock movement up
+1.81 (1.25%)
Company name
AbbVie Inc
Exchange
(NYSE
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-General
Market cap
258.23B
Ent value
370.55B
Price/Sales
4.45
Price/Book
14.94
Div yield
4.24%
Div growth
10.52%
Growth years
9
FCF payout
41.42%
Trailing P/E
21.82
Forward P/E
13.16
PEG
2.64
EPS growth
36.80%
1 year return
-10.71%
3 year return
11.80%
5 year return
9.34%
10 year return
11.71%
Last updated: 2023-12-06
Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
December 5, 2023

iO Charts is a Seeking Alpha partner

AbbVie has agreed to acquire ImmunoGen for $10 billion, nearly double its previous trading price. Read more about ABBV stock here.
December 3, 2023

iO Charts is a Seeking Alpha partner

BUSINESS INSIGHT

Revenues per Product Category ($M)

Loading...
Company comments

AbbVie was created through a spinoff from Abbott Laboratories in 2013

Humira is the world’s #1 global pharmaceutical product by a large margin

AbbVie acquired Allergan, the maker of Botox in 2020, hence the huge jump in revenues and the change in the segment classifications

Geographic Revenues ($M)

Loading...

DIVIDENDS

Dividend yield - 5y

Loading...
Dividend yield data
Dividend per share6.20
Dividend yield4.24%
Payout frequencyQuarterly
Maximum yield7.32%
Average yield4.73%
Minimum yield3.22%
Discount to avg yield-11.69%
Upside potential-10.47%
Yield as % of max yield57.88%

Yield distribution (inverse percentile) - 5y

Loading...
Yield distribution data
Dividend yield4.24%
Current yield distribution66.98%
Yield at 100% (Min)3.22%
Yield at 90%3.76%
Yield at 80%3.96%
Yield at 50% (Median)4.75%
Yield at 20%5.39%
Yield at 10%5.77%
Yield at 0% (Max)7.32%

Dividend per share

Loading...
Dividend per share data
Years of growth9 years
CCC statusDividend Challenger
Dividend per share6.20
Payout frequencyQuarterly
Ex-div date12 Jan 2024
EPS (TTM)6.66
EPS (1y forward)11.12
EPS growth (5y)36.80%
EPS growth (5y forward)8.27%

Dividend growth

Loading...
Please create a free account or log in to access this chart
Dividend growth data
ABBVS&P500
DGR MR4.73%-3.37%
DGR TTM4.90%5.40%
DGR 3 years7.84%4.00%
DGR 5 years10.52%5.65%
DGR 10 years-7.37%
DGR 15 years-5.83%
Time since last change announced42 days
EPS growth (5y)36.80%
EPS growth (5y forward)8.27%

Payout ratio

Loading...
Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM84.85%41.42%
Average--
Forward55.76%-
AbbVie has agreed to acquire ImmunoGen in a $10.1 billion all-cash deal, aiming to revitalize its struggling oncology operations. Explore more details here.
December 2, 2023

iO Charts is a Seeking Alpha partner

AbbVie's acquisition of ImmunoGen accelerates growth opportunities in the biotech industry, expanding the drug pipeline. Find out more on the ABBV and IMGN deal.
December 1, 2023

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E21.82
Price to OCF10.35
Price to FCF10.65
Price to EBITDA11.17
EV to EBITDA16.03

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales4.45
Price to Book14.94
EV to Sales6.38

FINANCIALS

Per share

Loading...
Per share data
Current share count1.76B
EPS (TTM)6.66
FCF per share (TTM)13.64

Income statement

Loading...
Income statement data
Revenue (TTM)58.05B
Gross profit (TTM)40.64B
Operating income (TTM)18.36B
Net income (TTM)11.84B
EPS (TTM)6.66
EPS (1y forward)11.12

Margins

Loading...
Margins data
Gross margin (TTM)70.00%
Operating margin (TTM)31.63%
Profit margin (TTM)20.39%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash9.20B
Net receivables11.25B
Total current assets28.46B
Goodwill32.16B
Intangible assets67.44B
Property, plant and equipment0.00
Total assets138.81B
Accounts payable25.40B
Short/Current long term debt63.27B
Total current liabilities29.54B
Total liabilities121.52B
Shareholder's equity17.29B
Net tangible assets-82.34B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)24.94B
Capital expenditures (TTM)695.00M
Free cash flow (TTM)24.25B
Dividends paid (TTM)10.04B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity68.47%
Return on Assets8.53%
Return on Invested Capital14.69%
Cash Return on Invested Capital30.10%
Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
December 1, 2023

iO Charts is a Seeking Alpha partner

AbbVie's $10.1 billion acquisition of ImmunoGen, a leader in ovarian cancer treatment, strengthens its oncology portfolio for potential revenue growth. Learn more on ABBV stock here.
November 30, 2023

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open144.79
Daily high147.07
Daily low144.73
Daily Volume3.90M
All-time high174.96
1y analyst estimate163.87
Beta0.59
EPS (TTM)6.66
Dividend per share6.20
Ex-div date12 Jan 2024
Next earnings date7 Feb 2024

Downside potential

Loading...
Downside potential data
ABBVS&P500
Current price drop from All-time high-16.34%-4.80%
Highest price drop-48.88%-56.47%
Date of highest drop15 Aug 20199 Mar 2009
Avg drop from high-14.34%-11.47%
Avg time to new high19 days13 days
Max time to new high975 days1805 days
AbbVie Inc.'s $10.1B acquisition of ImmunoGen, Inc. diversifies its oncology pipeline and reduces its Humira reliance. Click for my take on the ABBV deal for IMGN.
November 30, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
November 30, 2023

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
ABBV (AbbVie Inc) company logo
Marketcap
258.23B
Marketcap category
Large-cap
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Employees
50000
SEC filings
CEO
Richard Gonzalez
Country
USA
City
North Chicago
Stock type
Common stock
CCC status
Dividend Challenger
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
AbbVie upgraded its guidance, raised its full-year revenue estimates, and adjusted its EPS outlook. Learn why I'm neutral on ABBV stock.
November 30, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
November 30, 2023

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
AbbVie's highlights include strong dividend growth, performance, valuation, and potential to outperform S&P 500 in the long-term. Read more on ABBV stock here.
November 30, 2023
The valuation of AbbVie is high compared to its growth prospects, making it unattractive. Read more to see our analysis on ABBV stock.
November 29, 2023
Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
November 29, 2023
AbbVie is a compelling value play with a 4.5% yield, strong performance, and a 4.7% dividend increase. Find out why ABBV stock is a Buy.
November 29, 2023
Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
November 27, 2023
Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
November 22, 2023
This article examines two healthcare stalwarts, AbbVie (ABBV) and Amgen (AMGN) through the lens of Lynch's approach. Check out which stock I prefer.
November 21, 2023
Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
November 16, 2023
Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
November 15, 2023
Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
November 7, 2023
iO Charts is a Seeking Alpha partnerNext page